Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 3/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.52 |
| ▸ | NT5E | P21589 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5360770 | 1.00 | HINT1 (0.56) | HINT1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL5360062 | 0.91 | EHMT1 (0.56) | HINT1ADORA3ADORA2AADORA2BADORA1 | |
| Thioguanosine SCHEMBL230739 | 0.90 | LMNA (0.62) | ADORA3ADORA2AADORA2BADORA1NT5E | |
| Thioguanosine SCHEMBL5557152 | 0.90 | LMNA (0.62) | ADORA3ADORA2AADORA2BADORA1NT5E | |
| Thioguanosine SCHEMBL10017757 | 0.90 | LMNA (0.62) | ADORA3ADORA2AADORA2BADORA1NT5E | |
| Thioguanosine SCHEMBL230740 | 0.90 | LMNA (0.62) | ADORA3ADORA2AADORA2BADORA1NT5E | |
| Thioguanosine SCHEMBL4527562 | 0.90 | LMNA (0.62) | ADORA3ADORA2AADORA2BADORA1NT5E | |
| Thioguanosine SCHEMBL2619736 | 0.90 | LMNA (0.62) | ADORA3ADORA2AADORA2BADORA1NT5E | |
| Thioguanosine SCHEMBL1981035 | 0.90 | LMNA (0.62) | ADORA3ADORA2AADORA2BADORA1NT5E | |
| Thioguanosine SCHEMBL14156817 | 0.90 | LMNA (0.62) | ADORA3ADORA2AADORA2BADORA1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | SPIRAL THERAPEUTICS INC. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | OTC, SLC26A4, OAT | HINT1 944/4885ADORA3 959/4885ADORA2A 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.